neuropsychological-tests

Complex occupations help protect our brains from aging-related cognitive decline

by

Cog­ni­tive aging: Work helps our brain (AAAS):

A recent study shows that work plays an active role in keep­ing our brains healthy. “We have demon­strat­ed the role of work­ing activ­i­ty on cog­ni­tive per­for­mance”. Pro­fes­sor Raf­fael­la Rumiati says … “Many stud­ies have been focused on the fac­tors influ­enc­ing our brain aging and dif­fer­ences in cog­ni­tive decline have been often observed in asso­ci­a­tion with edu­ca­tion or oth­er relat­ed to qual­i­ty of life. From our analy­sis it emerges that the type of work activ­i­ty also con­tributes to the dif­fer­ences in nor­mal and patho­log­i­cal cog­ni­tive aging”. [Read more…] about Com­plex occu­pa­tions help pro­tect our brains from aging-relat­ed cog­ni­tive decline

Six guidelines to navigate the Aduhelm controversy and (hopefully) help patients with Mild Cognitive Impairment and early-stage Alzheimer’s Disease

by

The approval of a con­tro­ver­sial new drug for Alzheimer’s dis­ease, Aduhelm, is shin­ing a spot­light on mild cog­ni­tive impair­ment — prob­lems with mem­o­ry, atten­tion, lan­guage or oth­er cog­ni­tive tasks that exceed changes expect­ed with nor­mal aging.

After ini­tial­ly indi­cat­ing that Aduhelm could be pre­scribed to any­one with demen­tia, the Food and Drug Admin­is­tra­tion now spec­i­fies that the pre­scrip­tion drug be giv­en to indi­vid­u­als with mild cog­ni­tive impair­ment or ear­ly-stage Alzheimer’s, the groups in which the med­ica­tion was studied.

Yet this nar­row­er rec­om­men­da­tion rais­es ques­tions. What does a diag­no­sis of mild cog­ni­tive impair­ment mean? Is Aduhelm appro­pri­ate for all peo­ple with mild cog­ni­tive impair­ment, or only some? And who should decide which patients qual­i­fy for treat­ment: demen­tia spe­cial­ists or pri­ma­ry care physi­cians? [Read more…] about Six guide­lines to nav­i­gate the Aduhelm con­tro­ver­sy and (hope­ful­ly) help patients with Mild Cog­ni­tive Impair­ment and ear­ly-stage Alzheimer’s Disease

Cognitive training, diet, exercise, and vascular management seen to improve cognition even in people with genetic predisposition for dementia (APOE e4)

by

___

How do genet­ics impact ear­ly inter­ven­tion for demen­tia? (Med­ical News Bulletin):

“Car­dio­vas­cu­lar and neu­ro­log­i­cal dis­eases, such as demen­tia, have been linked to dys­func­tion of a vari­a­tion of the apolipopro­tein E, or APOE, gene, called the APOE e4 allele…The Finnish Geri­atric Inter­ven­tion Study to Pre­vent Cog­ni­tive Impair­ment and Dis­abil­i­ty (FINGER) eval­u­at­ed whether the effec­tive­ness of lifestyle mod­i­fi­ca­tions for those at risk of Alzheimer’s dis­ease would be dif­fer­ent for those with or with­out the APOE e4 gene. [Read more…] about Cog­ni­tive train­ing, diet, exer­cise, and vas­cu­lar man­age­ment seen to improve cog­ni­tion even in peo­ple with genet­ic pre­dis­po­si­tion for demen­tia (APOE e4)

Study: Harnessing a virtual reality brain training game to diagnose mild cognitive impairment (MCI)

by

virtual supermarket.

Vir­tu­al real­i­ty brain train­ing game can detect mild cog­ni­tive impair­ment, a con­di­tion that often pre­dates Alzheimer’s dis­ease (press release):

“Geek researchers demon­strat­ed the poten­tial of a vir­tu­al super­mar­ket cog­ni­tive train­ing game as a screen­ing tool for patients with mild cog­ni­tive impair­ment (MCI) among a sam­ple of old­er adults…

In an arti­cle pub­lished in the Jour­nal of Alzheimer’s Dis­ease, the researchers [Read more…] about Study: Har­ness­ing a vir­tu­al real­i­ty brain train­ing game to diag­nose mild cog­ni­tive impair­ment (MCI)

CEO of Cambridge Cognition to speak at 2013 SharpBrains Summit

by

ruth-keir

Ruth Frances Keir runs Cam­bridge Cog­ni­tion (AIM: COG), one of the 10 Com­pa­nies to Watch in 2013/ 2014 accord­ing to our lat­est mar­ket report, which devel­ops and com­mer­cial­izes com­put­erised neu­ropsy­cho­log­i­cal tests used in a vari­ety of health­care and research set­tings. She joined the Cam­bridge Cog­ni­tion board ini­tial­ly in 2010 as a non-exec­u­tive direc­tor, bring­ing to it more than 26 years’ expe­ri­ence in research and busi­ness devel­op­ment posi­tions in the phar­ma­ceu­ti­cal indus­try, as well as a peri­od as Direc­tor of her own con­sul­tan­cy busi­ness, Archea Ltd.

–> To Learn More and Reg­is­ter, click on 2013 Sharp­Brains Vir­tual Sum­mit: Sep­tem­ber 19–20th, 2013

Cambridge Cognition, developer of computerised neuropsychological tests, to go public in the UK

by

cantabmobileCam­bridge Cog­ni­tion, one of the 10 Com­pa­nies to Watch in 2013/ 2014 accord­ing to our lat­est mar­ket report, just announced its plans to go pub­lic in the UK’s AIM market.

Cam­bridge Cog­ni­tion in £15M AIM IPO (Busi­ness Week­ly): “… the move will [Read more…] about Cam­bridge Cog­ni­tion, devel­op­er of com­put­erised neu­ropsy­cho­log­i­cal tests, to go pub­lic in the UK